Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors

NCT ID: NCT04981691

Last Updated: 2021-09-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-10-01
• Study Completion Date: 2022-07-09

Brief Summary

The goal of this clinical trial is to study the safety, efficacy, and pharmacokinetics of mRNA-engineered anti-Mesothelin (MESO) Chimeric Antigen Receptor T-Cell (CAR-T cells) therapy in patients with mesothelin expression-positive, advanced solid tumors that have failed at least first-line or second-line therapy.

Detailed Description

This phase I study is being conducted to establish safety, pharmacokinetics, and preliminary efficacy of intravenous (IV) mRNA electroporated fully-humanized anti-MESO re-directed autologous T cell administration in patients with chemotherapy-refractory metastatic solid tumors.

The study will adopt the "3+3" dose escalation design exploring two doses of 1×109 and 3×109. The administration is planned to infuse 3 times a week for 2 consecutive weeks.

• The subjects will receive a total dose of 1x109 RNA transduced anti-MESO CAR-T cells in the first week, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. If there is no obvious dose-limiting toxicity (DLT) after the first week of infusion, three times consecutive infusions of 1x109 anti-MESO CAR-T cells each time is planned in the second week. Each subject needs to be observed for at least 2 weeks (14 days) after completing the last infusion. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of anti-MESO CAR-T cells.

Conditions

Refractory Malignant Solid Neoplasm

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

anti-MESO CAR-T cells

The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d from day-4 to day-2. Subjects will be treated with six administrations of anti-MESO CAR-T cells three times weekly (Monday-Wednesday-Friday) for two weeks. In the first week, total 1×109 or 3×109 will be infused, the second week is to plan three times consecutive infusions of 1x109 or 3×109 anti-MESO CAR-T cells each time.

Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and be 28 days from their last infusion before the next subject can be treated.

Interventions:

• Drug: anti-MESO CAR-T cells
• Drug: Fludarabine
• Drug: Cyclophosphamide

Group Type: EXPERIMENTAL

anti-MESO CAR T cells

Intervention Type: BIOLOGICAL

Autologous genetically modified anti-MESO CAR T cells

Interventions

anti-MESO CAR T cells

Autologous genetically modified anti-MESO CAR T cells

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Ability to understand and the willingness to provide written informed consent.

2. Advanced pancreatic cancer, ovarian cancer, malignant mesothelioma, gastric cancer, bowel cancer, etc., diagnosed by histopathological or cytological examination, but not limited to subjects with various advanced solid tumors.

3. IHC test showed Mesothelin positive expression at least 1+ in tumor tissue

4. Age no less than 18 years.

5. Life expectancy greater than 3 months.

6. According to the RECIST (Response Evaluation Criteria in Solid Tumors) standard, there must be measurable lesions.

7. Evidence of metastatic disease and failure of at least 1 prior chemotherapy for metastatic disease. During the last treatment or after the treatment, the disease progressed and was confirmed (the investigator judged according to the RECIST 1.1 standard).

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 during the screening period and before apheresis.

9. Adequate liver/bone marrow function.

10. Female subjects must meet the following conditions: infertility or fertility and use high-efficiency contraceptive measures.

11. Male subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for 3 months following the last dose of the study cell infusion. Moreover, all men are absolutely prohibited from donating sperm within 1 year after receiving the last study treatment infusion.

Exclusion Criteria

1. Participated in any other trial in which receipt of an investigational study drug occurred within 28 days prior to entry into the study.

2. Received any anticancer medication in the 2 weeks prior to receiving their first dose of study treatment, including but not limited to surgery, systemic chemotherapy, radiotherapy, intervention, etc.

3. Uncontrolled thyroid dysfunction (serum thyroid hormone determination TT4, TT3, FT3, FT4, and serum thyroid-stimulating hormone TSH) are not suitable for enrolling in the study;

4. Pregnant or breastfeeding female, or not willing to take contraception measures during the study.

5. Any uncontrollable active infection, including but not limited to active tuberculosis; HBV infection (including HBsAg positive, or HBcAb positive and HBV DNA positive); HIV, syphilis, hepatitis C positive or suffering from other fatal viruses, Bacterial disease

6. Administrated with steroids (5 mg/day or more dexamethasone, or equivalent hormone drugs) within the past two weeks;

7. Other uncontrolled diseases may cause abnormal death of the patient;

8. Active autoimmune disease (including but not limited to: systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within the past 4 weeks.

9. Previously allergic to immunotherapy, tocilizumab, cyclophosphamide, fludarabine, and other related drugs, previous history of severe allergies, to research product excipients (such as human serum albumin, DMSO, and dextran 40 ); people who have a history of penicillin allergy and have a positive skin test at the time of screening.

10. Congestive heart failure, uncontrolled cardiac arrhythmia, etc.

11. Uncontrollable massive ascites, that cannot be drained by standard methods;

12. Intestinal obstruction or CT suggesting omental cake-like peritoneal metastasis, or repeated uncontrollable incomplete intestinal obstruction.

13. Have received any genetic engineering modified T cell therapy (including CAR T, TCR T cell).

14. Uncontrolled brain metastasis or mental illness.

15. Suffered from other uncured malignant tumors within the past 3 years or at the same time.

16. The blood oxygen saturation ≤95% at the time of screening and before apheresis.

17. Can't be followed up or obey protocol.

18. The investigator believes that it is not appropriate to participate in the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

UTC Therapeutics Inc.

INDUSTRY

Sponsor Role: collaborator

Ruijin Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jun Zhang

Chief of Department of Oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jun Zhang, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Ruijin Hospital

Locations

Department of Oncology, Ruijin Hospital

Shanghai, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Jun Zhang, MD, PhD

Role: CONTACT

junzhang10977@sjtu.edu.cn

0086-13818332497

Yan Shi, MD, PhD

Role: CONTACT

sy_rjh@aliyun.com

0086-13810561979

Facility Contacts

Jun Zhang, MD & Ph. D

Role: primary

junzhang10977@sjtu.edu.cn

+86-13818332497

Other Identifiers

Amaretto

Identifier Type: -

Identifier Source: org_study_id